Edwards LifesciencesEW

關於Edwards Lifesciences

Edwards Lifesciences designs, manufactures, and sells medical technologies for structural heart disease and critical care monitoring, with a portfolio built around heart valve therapies. Its transcatheter aortic valve replacement (TAVR) franchise, anchored by the SAPIEN platform, is by far the largest business and the dominant profit engine, treating aortic stenosis through catheter-based implantation rather than open-chest surgery. Surgical structural heart contributes a smaller share through tissue heart valves and repair products for the aortic and mitral positions. A growing transcatheter mitral and tricuspid therapies segment addresses valve regurgitation with devices such as PASCAL and EVOQUE. The company is a pure-play structural heart business following the divestiture of its critical care monitoring arm.

Holders track the pace of TAVR market growth in the United States, Europe, and Japan, where penetration of eligible aortic stenosis patients remains a defining variable, and competitive dynamics against Medtronic's CoreValve platform. Regulatory milestones from the U.S. Food and Drug Administration and reimbursement decisions by the Centers for Medicare and Medicaid Services materially shape adoption curves. Ongoing randomized clinical trials that expand indications into asymptomatic and moderate patient populations are closely followed. Intellectual property litigation with peers, foreign exchange exposure through a substantial international business, capital deployment between research and development, tuck-in acquisitions, and share repurchases, and the concentration of profit in a single therapeutic category are structural considerations for serious holders.

Edwards traces its roots to 1958, when engineer Miles Lowell Edwards and cardiac surgeon Albert Starr developed the first commercially successful artificial heart valve, the Starr-Edwards caged-ball valve. The business operated for decades within Baxter International after its 1985 acquisition of American Hospital Supply Corporation, and was spun off as an independent public company on the New York Stock Exchange in April 2000 under chief executive Michael Mussallem. The company acquired Percutaneous Valve Technologies in 2004, which brought in the transcatheter valve technology that became SAPIEN, first approved in the United States in 2011. In 2024 Edwards divested its Critical Care segment to Becton Dickinson, sharpening its focus on structural heart.

Revenue is generated primarily through sales of implantable devices to hospitals and cardiac centers, where interventional cardiologists and cardiothoracic surgeons implant valves in procedures typically reimbursed under diagnosis-related group payments by government and private insurers. Contracts are commonly negotiated with hospital purchasing groups and integrated delivery networks, with pricing influenced by procedural volumes and clinical outcomes data. Competitive position rests on clinical trial evidence, valve durability, deliverability of the delivery system, and physician training programs cultivated over years. The principal TAVR competitor globally is Medtronic, while Abbott competes prominently in transcatheter mitral repair with MitraClip. The United States is the largest single geography, though Europe, Japan, and the rest of world together contribute a meaningful share of sales.

公司簡介由LineVest編輯部撰寫。屬新聞報導，非投資建議。 委託撰寫Edwards Lifesciences的SEC完整報告 →